
Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
Ophthalmology Times' Sheryl Stevenson speaks with Julie Speed, chief commercial officer of Eyevance Pharmaceuticals, on what's on the agenda for the company's porfolio this year with product launches during the 2020 ASCRS virtual meeting.
See more ASCRS coverage here




